Rhythm Pharmaceuticals, Inc. (RYTM)

Rhythm Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	53.89	60.41	128.01	59.58	101.26	62.7
Short-Term Investments	147.77	215.77	205.61	235.61	71.94	230.17
Cash & Cash Equivalents	201.66	276.17	333.62	295.18	173.2	292.86
Cash Growth	-31.62%	-17.22%	13.02%	70.43%	-40.86%	16.00%
Receivables	14.7	14.87	6.22	1.03	0	0
Inventory	8.51	8.62	2.92	0.11	0	0
Other Current Assets	10.89	8.6	11.48	12.07	8.47	9.54
Total Current Assets	235.75	308.27	354.24	308.39	181.67	302.4
Property, Plant & Equipment	1.82	2.12	3.38	4.34	5	5.72
Goodwill and Intangibles	6.82	7.03	7.88	4.66	0	0
Other Long-Term Assets	14.26	15.33	16.98	12.14	0.4	0.4
Total Long-Term Assets	22.9	24.48	28.25	21.14	5.41	6.12
Total Assets	258.65	332.75	382.48	329.52	187.07	308.52
Accounts Payable	7.55	4.89	4.8	5.74	4.9	10.42
Deferred Revenue	1.29	1.29	1.43	7	0	0
Current Debt	0.79	0.77	0.68	0.61	0.54	0.47
Other Current Liabilities	44.53	48.26	32.89	30.08	12.56	13.53
Total Current Liabilities	54.16	55.2	39.81	43.43	17.99	24.42
Long-Term Debt	0.28	0.49	1.26	1.95	2.55	3.09
Other Long-Term Liabilities	142.63	107.29	77.15	0	0	0
Total Long-Term Liabilities	142.91	107.78	78.41	1.95	2.55	3.09
Total Liabilities	197.07	162.99	118.22	45.37	20.55	27.5
Total Debt	1.08	1.26	1.94	2.55	3.09	3.56
Debt Growth	-39.53%	-35.19%	-23.79%	-17.34%	-13.27%	-
Retained Earnings	-1,036.11	-894.74	-710.06	-528.94	-459.33	-325.33
Comprehensive Income	-0.18	0.13	-0.09	-0	0.05	0
Shareholders' Equity	61.58	169.76	264.26	284.15	166.53	281.02
Net Cash / Debt	200.58	274.91	331.67	292.63	170.11	289.3
Net Cash / Debt Growth	-31.57%	-17.11%	13.34%	72.03%	-41.20%	14.59%
Net Cash Per Share	3.34	4.77	6.36	5.90	3.85	7.94
Working Capital	181.59	253.07	314.43	264.96	163.67	277.99
Book Value Per Share	1.02	2.94	5.07	5.73	3.77	7.72

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).